Title: Role of O6-methylguanine DNA methyltransferase status as predictive factor for alkylatin-based chemotherapy in advanced neuroendocrine tumors: State of the art.
Maria Grazia Maratta, Vincenzo Bagnardi, Nicola Fazio
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the predictive role of O6-Methylguanine DNA Methyltransferase (MGMT) status in advanced neuroendocrine tumors (NETs) treated with alkylating agents, including temozolomide (TMZ). Among 1826 NET patients, those with MGMT deficiency showed higher overall response rates and progression-free survival compared to MGMT-proficient patients. The findings suggest MGMT status may influence treatment efficacy, though routine testing is not currently recommended.
Key findings
- MGMT-deficient NETs had higher overall response rates compared to MGMT-proficient NETs.
- Progression-free survival was also greater in MGMT-deficient patients.
- The review included 23 studies with 1826 NET patients, 1462 treated with alkylating agents.
- MGMT status was assessed in 1092 patients using various techniques.
Why it matters
Understanding the predictive value of MGMT status could help tailor chemotherapy approaches in advanced neuroendocrine tumors, potentially improving patient outcomes. However, the variability in assessment methods complicates clinical application.
What to keep in mind
The high heterogeneity of the studies and techniques used may introduce interpretation biases.